Now showing items 41-60 of 3076

    • Physicians, paraproteins and progress: diagnosis and management of myeloma. 

      Pawlyn, C; Jackson, GH (2019-02-02)
      Myeloma outcomes have improved dramatically over the last decade as a result of novel therapies, several of which are now commonly continued to disease relapse. Physicians who do not work in haematology are therefore more ...
    • Dependence of inertial cavitation induced by high intensity focused ultrasound on transducer F-number and nonlinear waveform distortion. 

      Khokhlova, T; Rosnitskiy, P; Hunter, C; Maxwell, A; Kreider, W; Ter Haar, G; Costa, M; Sapozhnikov, O; Khokhlova, V (2018-09)
      Pulsed high intensity focused ultrasound was shown to enhance chemotherapeutic drug uptake in tumor tissue through inertial cavitation, which is commonly assumed to require peak rarefactional pressures to exceed a certain ...
    • ESR1 mutations in metastatic lobular breast cancer patients. 

      Desmedt, C; Pingitore, J; Rothé, F; Marchio, C; Clatot, F; Rouas, G; Richard, F; Bertucci, F; Mariani, O; Galant, C; Fribbens, C; O'Leary, B; van den Eynden, G; Salgado, R; Turner, NC; Piccart, M; Vincent-Salomon, A; Pruneri, G; Larsimont, D; Sotiriou, C (2019)
      Invasive lobular breast cancer (ILC) represents the second most common histology of breast cancer after invasive ductal breast cancer (IDC), accounts for up to 15% of all invasive cases and generally express the estrogen ...
    • Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. 

      Vyse, S; Huang, PH (2019)
      Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic drivers in non-small cell lung cancer (NSCLC). ...
    • MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Anti-angiogenic Treatment. 

      Zormpas-Petridis, K; Jerome, NP; Blackledge, MD; Carceller, F; Poon, E; Clarke, M; McErlean, CM; Barone, G; Koers, A; Vaidya, SJ; Marshall, LV; Pearson, ADJ; Moreno, L; Anderson, J; Sebire, N; McHugh, K; Koh, D-M; Yuan, Y; Chesler, L; Robinson, SP; Jamin, Y (2019-03-15)
      Childhood neuroblastoma is a hypervascular tumor of neural origin for which antiangiogenic drugs are currently being evaluated; however, predictive biomarkers of treatment response, crucial for successful delivery of ...
    • C9orf72 arginine-rich dipeptide proteins interact with ribosomal proteins in vivo to induce a toxic translational arrest that is rescued by eIF1A. 

      Moens, TG; Niccoli, T; Wilson, KM; Atilano, ML; Birsa, N; Gittings, LM; Holbling, BV; Dyson, MC; Thoeng, A; Neeves, J; Glaria, I; Yu, L; Bussmann, J; Storkebaum, E; Pardo, M; Choudhary, JS; Fratta, P; Partridge, L; Isaacs, AM (2019-03)
      A GGGGCC hexanucleotide repeat expansion within the C9orf72 gene is the most common genetic cause of both amyotrophic lateral sclerosis and frontotemporal dementia. Sense and antisense repeat-containing transcripts undergo ...
    • First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. 

      Shimomura, A; Yamamoto, N; Kondo, S; Fujiwara, Y; Suzuki, S; Yanagitani, N; Horiike, A; Kitazono, S; Ohyanagi, F; Doi, T; Kuboki, Y; Kawazoe, A; Shitara, K; Ohno, I; Banerji, U; Sundar, R; Ohkubo, S; Calleja, EM; Nishio, M (2019-03)
      HSP90 is involved in stability and function of cancer-related proteins. This study was conducted to define the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy of TAS-116, a novel class, ...
    • Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. 

      Turner, NC; Liu, Y; Zhu, Z; Loi, S; Colleoni, M; Loibl, S; DeMichele, A; Harbeck, N; André, F; Bayar, MA; Michiels, S; Zhang, Z; Giorgetti, C; Arnedos, M; Huang Bartlett, C; Cristofanilli, M (2019-02-26)
      PURPOSE: A large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to fulvestrant. METHODS: The PALOMA-3 ( ClinicalTrials.gov identifier: NCT01942135) ...
    • Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients. 

      Zheng, G; Chattopadhyay, S; Sud, A; Sundquist, K; Sundquist, J; Försti, A; Houlston, RS; Hemminki, A; Hemminki, K (2019-03-26)
    • Genome-wide association study of germline variants and breast cancer-specific mortality. 

      Escala-Garcia, M; Guo, Q; Dörk, T; Canisius, S; Keeman, R; Dennis, J; Beesley, J; Lecarpentier, J; Bolla, MK; Wang, Q; Abraham, J; Andrulis, IL; Anton-Culver, H; Arndt, V; Auer, PL; Beckmann, MW; Behrens, S; Benitez, J; Bermisheva, M; Bernstein, L; Blomqvist, C; Boeckx, B; Bojesen, SE; Bonanni, B; Børresen-Dale, A-L; Brauch, H; Brenner, H; Brentnall, A; Brinton, L; Broberg, P; Brock, IW; Brucker, SY; Burwinkel, B; Caldas, C; Caldés, T; Campa, D; Canzian, F; Carracedo, A; Carter, BD; Castelao, JE; Chang-Claude, J; Chanock, SJ; Chenevix-Trench, G; Cheng, T-YD; Chin, S-F; Clarke, CL; NBCS Collaborators; Cordina-Duverger, E; Couch, FJ; Cox, DG; Cox, A; Cross, SS; Czene, K; Daly, MB; Devilee, P; Dunn, JA; Dunning, AM; Durcan, L; Dwek, M; Earl, HM; Ekici, AB; Eliassen, AH; Ellberg, C; Engel, C; Eriksson, M; Evans, DG; Figueroa, J; Flesch-Janys, D; Flyger, H; Gabrielson, M; Gago-Dominguez, M; Galle, E; Gapstur, SM; García-Closas, M; García-Sáenz, JA; Gaudet, MM; George, A; Georgoulias, V; Giles, GG; Glendon, G; Goldgar, DE; González-Neira, A; Alnæs, GIG; Grip, M; Guénel, P; Haeberle, L; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Hankinson, S; Harkness, EF; Harrington, PA; Hart, SN; Hartikainen, JM; Hein, A; Hillemanns, P; Hiller, L; Holleczek, B; Hollestelle, A; Hooning, MJ; Hoover, RN; Hopper, JL; Howell, A; Huang, G; Humphreys, K; Hunter, DJ; Janni, W; John, EM; Jones, ME; Jukkola-Vuorinen, A; Jung, A; Kaaks, R; Kabisch, M; Kaczmarek, K; Kerin, MJ; Khan, S; Khusnutdinova, E; Kiiski, JI; Kitahara, CM; Knight, JA; Ko, Y-D; Koppert, LB; Kosma, V-M; Kraft, P; Kristensen, VN; Krüger, U; Kühl, T; Lambrechts, D; Le Marchand, L; Lee, E; Lejbkowicz, F; Li, L; Lindblom, A; Lindström, S; Linet, M; Lissowska, J; Lo, W-Y; Loibl, S; Lubiński, J; Lux, MP; MacInnis, RJ; Maierthaler, M; Maishman, T; Makalic, E; Mannermaa, A; Manoochehri, M; Manoukian, S; Margolin, S; Martinez, ME; Mavroudis, D; McLean, C; Meindl, A; Middha, P; Miller, N; Milne, RL; Moreno, F; Mulligan, AM; Mulot, C; Nassir, R; Neuhausen, SL; Newman, WT; Nielsen, SF; Nordestgaard, BG; Norman, A; Olsson, H; Orr, N; Pankratz, VS; Park-Simon, T-W; Perez, JIA; Pérez-Barrios, C; Peterlongo, P; Petridis, C; Pinchev, M; Prajzendanc, K; Prentice, R; Presneau, N; Prokofieva, D; Pylkäs, K; Rack, B; Radice, P; Ramachandran, D; Rennert, G; Rennert, HS; Rhenius, V; Romero, A; Roylance, R; Saloustros, E; Sawyer, EJ; Schmidt, DF; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schumacher, F; Schwentner, L; Scott, RJ; Scott, C; Seynaeve, C; Shah, M; Simard, J; Smeets, A; Sohn, C; Southey, MC; Swerdlow, AJ; Talhouk, A; Tamimi, RM; Tapper, WJ; Teixeira, MR; Tengström, M; Terry, MB; Thöne, K; Tollenaar, RAEM; Tomlinson, I; Torres, D; Truong, T; Turman, C; Turnbull, C; Ulmer, H-U; Untch, M; Vachon, C; van Asperen, CJ; van den Ouweland, AMW; van Veen, EM; Wendt, C; Whittemore, AS; Willett, W; Winqvist, R; Wolk, A; Yang, XR; Zhang, Y; Easton, DF; Fasching, PA; Nevanlinna, H; Eccles, DM; Pharoah, PDP; Schmidt, MK (2019-03)
      BACKGROUND: We examined the associations between germline variants and breast cancer mortality using a large meta-analysis of women of European ancestry. METHODS: Meta-analyses included summary estimates based on Cox models ...
    • Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer 

      Bertholet, J; Hunt, A; Dunlop, A; Bird, T; Mitchell, RA; Oelfke, U; Nill, S; Aitken, K
    • Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer. 

      Bertholet, J; Hunt, A; Dunlop, A; Bird, T; Mitchell, RA; Oelfke, U; Nill, S; Aitken, K (2019-05)
      Objectives: To determine the potential for dose escalation to a biological equivalent dose BED10 ≅ 100 Gy in hypofractionated radiotherapy for locally advanced pancreatic cancer (LAPC). Materials and methods: Ten unselected ...
    • Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer. 

      Bertholet, J; Hunt, A; Dunlop, A; Bird, T; Mitchell, RA; Oelfke, U; Nill, S; Aitken, K (2019-05)
      Objectives: To determine the potential for dose escalation to a biological equivalent dose BED10 ≅ 100 Gy in hypofractionated radiotherapy for locally advanced pancreatic cancer (LAPC). Materials and methods: Ten unselected ...
    • Solution NMR assignment of the ARC4 domain of human tankyrase 2. 

      Zaleska, M; Pollock, K; Collins, I; Guettler, S; Pfuhl, M (2019-04)
      Tankyrases are poly(ADP-ribose)polymerases (PARPs) which recognize their substrates via their ankyrin repeat cluster (ARC) domains. The human tankyrases (TNKS/TNKS2) contain five ARCs in their extensive N-terminal region; ...
    • Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity. 

      Watts, E; Heidenreich, D; Tucker, E; Raab, M; Strebhardt, K; Chesler, L; Knapp, S; Bellenie, B; Hoelder, S (2019-03-14)
      Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fraction of high-risk ...
    • Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. 

      Leongamornlert, DA; Saunders, EJ; Wakerell, S; Whitmore, I; Dadaev, T; Cieza-Borrella, C; Benafif, S; Brook, MN; Donovan, JL; Hamdy, FC; Neal, DE; Muir, K; Govindasami, K; Conti, DV; Kote-Jarai, Z; Eeles, RA (2019-02-15)
      BACKGROUND: Rare germline mutations in DNA repair genes are associated with prostate cancer (PCa) predisposition and prognosis. OBJECTIVE: To quantify the frequency of germline DNA repair gene mutations in UK PCa cases and ...
    • Dosimetric accuracy of dynamic couch rotation during volumetric modulated arc therapy (DCR-VMAT) for primary brain tumours. 

      Smyth, G; Evans, PM; Bamber, JC; Mandeville, HC; Rollo Moore, A; Welsh, LC; Saran, FH; Bedford, JL (2019-04-05)
      Radiotherapy treatment plans using dynamic couch rotation during volumetric modulated arc therapy (DCR-VMAT) reduce the dose to organs at risk (OARs) compared to coplanar VMAT, while maintaining the dose to the planning ...
    • Mechanical and Systems Biology of Cancer. 

      Spill, F; Bakal, C; Mak, M (2018)
      Mechanics and biochemical signaling are both often deregulated in cancer, leading toincreased cell invasiveness, proliferation, and survival. The dynamics and interactions of cytoskeletal components control basic mechanical ...
    • Ultrafast glutamate sensors resolve high-frequency release at Schaffer collateral synapses. 

      Helassa, N; Dürst, CD; Coates, C; Kerruth, S; Arif, U; Schulze, C; Wiegert, JS; Geeves, M; Oertner, TG; Török, K (2018-05-22)
      Glutamatergic synapses display a rich repertoire of plasticity mechanisms on many different time scales, involving dynamic changes in the efficacy of transmitter release as well as changes in the number and function of ...